All In Biotech

Drug Trial Radar · NCT01220492

Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis

Phase 1/2 Study of UC-MSC Treatment for the Evaluation the Efficacy and Safety in Patients With Liver Cirrhosis

Last checked: Nov 19, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 266 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

266

Actual

Start

May 2009

Primary completion

Apr 2016

Study completion Apr 2016

Sponsor

Lead sponsor
Beijing 302 HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. The liver transplantation is one of the only effective therapies available to such patients. However, lack of donors, surgical complications, rejection, and high cost are it's serious problems. The potential for stem cells to differentiate into hepatocytes cells was recently confirmed. Particularly, autologous bone marrow-derived mesenchymal stem cell (BM-MSC) has been demonstrated to decrease MELD score and increase serum albumin in the patients with decompensated liver cirrhosis. Therefore, the investigators propose a hypothesis that umbilical cord-derived MSCs (UC-MSC) can also improve the disease conditions of LC patients, particularly reducing the decompensated conditions in these patients.

Conditions

  • Liver Cirrhosis

Interventions

  • conventional plus MSC treatmentDrug

    received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.

  • conventional plus placebo treatmentDrug

    received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. survival timeTime frame: 75 months
  2. incidence of HCC eventsTime frame: 75 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing 302 Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.